300 related articles for article (PubMed ID: 21305609)
1. Regulation of RANKL-induced osteoclastogenesis by TGF-β through molecular interaction between Smad3 and Traf6.
Yasui T; Kadono Y; Nakamura M; Oshima Y; Matsumoto T; Masuda H; Hirose J; Omata Y; Yasuda H; Imamura T; Nakamura K; Tanaka S
J Bone Miner Res; 2011 Jul; 26(7):1447-56. PubMed ID: 21305609
[TBL] [Abstract][Full Text] [Related]
2. Maslinic acid suppresses osteoclastogenesis and prevents ovariectomy-induced bone loss by regulating RANKL-mediated NF-κB and MAPK signaling pathways.
Li C; Yang Z; Li Z; Ma Y; Zhang L; Zheng C; Qiu W; Wu X; Wang X; Li H; Tang J; Qian M; Li D; Wang P; Luo J; Liu M
J Bone Miner Res; 2011 Mar; 26(3):644-56. PubMed ID: 20814972
[TBL] [Abstract][Full Text] [Related]
3. Transforming growth factor beta affects osteoclast differentiation via direct and indirect actions.
Quinn JM; Itoh K; Udagawa N; Hausler K; Yasuda H; Shima N; Mizuno A; Higashio K; Takahashi N; Suda T; Martin TJ; Gillespie MT
J Bone Miner Res; 2001 Oct; 16(10):1787-94. PubMed ID: 11585342
[TBL] [Abstract][Full Text] [Related]
4. The 4-1BB ligand and 4-1BB expressed on osteoclast precursors enhance RANKL-induced osteoclastogenesis via bi-directional signaling.
Yang J; Park OJ; Lee YJ; Jung HM; Woo KM; Choi Y
Eur J Immunol; 2008 Jun; 38(6):1598-609. PubMed ID: 18421790
[TBL] [Abstract][Full Text] [Related]
5. JNK/c-Jun signaling mediates an anti-apoptotic effect of RANKL in osteoclasts.
Ikeda F; Matsubara T; Tsurukai T; Hata K; Nishimura R; Yoneda T
J Bone Miner Res; 2008 Jun; 23(6):907-14. PubMed ID: 18251700
[TBL] [Abstract][Full Text] [Related]
6. Epigallocatechin-3-gallate inhibits osteoclastogenesis by down-regulating c-Fos expression and suppressing the nuclear factor-kappaB signal.
Lee JH; Jin H; Shim HE; Kim HN; Ha H; Lee ZH
Mol Pharmacol; 2010 Jan; 77(1):17-25. PubMed ID: 19828731
[TBL] [Abstract][Full Text] [Related]
7. Identification of Nedd9 as a TGF-β-Smad2/3 Target Gene Involved in RANKL-Induced Osteoclastogenesis by Comprehensive Analysis.
Omata Y; Nakamura S; Koyama T; Yasui T; Hirose J; Izawa N; Matsumoto T; Imai Y; Seo S; Kurokawa M; Tsutsumi S; Kadono Y; Morimoto C; Aburatani H; Miyamoto T; Tanaka S
PLoS One; 2016; 11(6):e0157992. PubMed ID: 27336669
[TBL] [Abstract][Full Text] [Related]
8. 12-O-tetradecanoylphorbol-13-acetate (TPA) inhibits osteoclastogenesis by suppressing RANKL-induced NF-kappaB activation.
Wang C; Steer JH; Joyce DA; Yip KH; Zheng MH; Xu J
J Bone Miner Res; 2003 Dec; 18(12):2159-68. PubMed ID: 14672351
[TBL] [Abstract][Full Text] [Related]
9. Licorice isoliquiritigenin suppresses RANKL-induced osteoclastogenesis in vitro and prevents inflammatory bone loss in vivo.
Zhu L; Wei H; Wu Y; Yang S; Xiao L; Zhang J; Peng B
Int J Biochem Cell Biol; 2012 Jul; 44(7):1139-52. PubMed ID: 22521613
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of RANKL-induced osteoclastogenesis by (-)-DHMEQ, a novel NF-kappaB inhibitor, through downregulation of NFATc1.
Takatsuna H; Asagiri M; Kubota T; Oka K; Osada T; Sugiyama C; Saito H; Aoki K; Ohya K; Takayanagi H; Umezawa K
J Bone Miner Res; 2005 Apr; 20(4):653-62. PubMed ID: 15765185
[TBL] [Abstract][Full Text] [Related]
11. Epidermal growth factor receptor regulates osteoclast differentiation and survival through cross-talking with RANK signaling.
Yi T; Lee HL; Cha JH; Ko SI; Kim HJ; Shin HI; Woo KM; Ryoo HM; Kim GS; Baek JH
J Cell Physiol; 2008 Nov; 217(2):409-22. PubMed ID: 18543257
[TBL] [Abstract][Full Text] [Related]
12. Genomewide comprehensive analysis reveals critical cooperation between Smad and c-Fos in RANKL-induced osteoclastogenesis.
Omata Y; Yasui T; Hirose J; Izawa N; Imai Y; Matsumoto T; Masuda H; Tokuyama N; Nakamura S; Tsutsumi S; Yasuda H; Okamoto K; Takayanagi H; Hikita A; Imamura T; Matsuo K; Saito T; Kadono Y; Aburatani H; Tanaka S
J Bone Miner Res; 2015 May; 30(5):869-77. PubMed ID: 25431176
[TBL] [Abstract][Full Text] [Related]
13. TRAF2 is essential for TNF-alpha-induced osteoclastogenesis.
Kanazawa K; Kudo A
J Bone Miner Res; 2005 May; 20(5):840-7. PubMed ID: 15824857
[TBL] [Abstract][Full Text] [Related]
14. Activated platelets positively regulate RANKL-mediated osteoclast differentiation.
Weicht B; Maitz P; Kandler B; Fischer MB; Watzek G; Gruber R
J Cell Biochem; 2007 Dec; 102(5):1300-7. PubMed ID: 17957725
[TBL] [Abstract][Full Text] [Related]
15. Pim-1 regulates RANKL-induced osteoclastogenesis via NF-κB activation and NFATc1 induction.
Kim K; Kim JH; Youn BU; Jin HM; Kim N
J Immunol; 2010 Dec; 185(12):7460-6. PubMed ID: 21068407
[TBL] [Abstract][Full Text] [Related]
16. 2-Methoxystypandrone represses RANKL-mediated osteoclastogenesis by down-regulating formation of TRAF6-TAK1 signalling complexes.
Chiou WF; Liao JF; Huang CY; Chen CC
Br J Pharmacol; 2010 Sep; 161(2):321-35. PubMed ID: 20735418
[TBL] [Abstract][Full Text] [Related]
17. Mechanisms involved in enhancement of osteoclast formation by activin-A.
Kajita T; Ariyoshi W; Okinaga T; Mitsugi S; Tominaga K; Nishihara T
J Cell Biochem; 2018 Aug; 119(8):6974-6985. PubMed ID: 29737562
[TBL] [Abstract][Full Text] [Related]
18. Cyclic adenosine monophosphate/protein kinase A mediates parathyroid hormone/parathyroid hormone-related protein receptor regulation of osteoclastogenesis and expression of RANKL and osteoprotegerin mRNAs by marrow stromal cells.
Kondo H; Guo J; Bringhurst FR
J Bone Miner Res; 2002 Sep; 17(9):1667-79. PubMed ID: 12211438
[TBL] [Abstract][Full Text] [Related]
19. RGS18 acts as a negative regulator of osteoclastogenesis by modulating the acid-sensing OGR1/NFAT signaling pathway.
Iwai K; Koike M; Ohshima S; Miyatake K; Uchiyama Y; Saeki Y; Ishii M
J Bone Miner Res; 2007 Oct; 22(10):1612-20. PubMed ID: 17576169
[TBL] [Abstract][Full Text] [Related]
20. DICAM inhibits osteoclast differentiation through attenuation of the integrin αVβ3 pathway.
Jung YK; Han SW; Kim GW; Jeong JH; Kim HJ; Choi JY
J Bone Miner Res; 2012 Sep; 27(9):2024-34. PubMed ID: 22492581
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
